Skip to main content
U.S. flag

An official website of the United States government

Milestone 5.D

AD Related Dementias – Specific

Prepare for and initiate clinical trials that aim to alleviate or slow the course of LBD symptoms, and delay or prevent the onset of disease.

Success Criteria

  • Establish a clinical trial network with the personnel and infrastructure that can carry out LBD clinical trials.
  • Fund research for the development and validation of clinical tools to track cognitive changes and other symptoms that occur in LBD.
  • Initiate one or more clinical trials that test prospective therapies based on pharmaceutical approaches, gene therapy, regenerative medicine, surgical interventions, or non-pharmacological approaches to prevent or alter LBD processes.

Summary of Key Accomplishments

NIH has funded three early phase clinical trials for LBD since the last ADRD Summit in 2019, and NINDS recently issued a new request for applications to conduct additional Phase 2 and 3 Lewy Body Dementia (LBD) clinical trials (RFA NS21-008).

One Phase 2 trial in individuals with dementia with Lewy bodies (DLB) is testing the effect of a new drug (CT1812) that displaces beta-amyloid and alpha-synuclein from a receptor at neuronal synapses.

Another early phase clinical trial is evaluating whether citalopram, a drug that is FDA-approved to treat depression and is believed to slow accumulation of beta-amyloid in the brain, will prevent the development of dementia in Parkinson's disease and progression to PD dementia.

A third trial is evaluating the effects of Nilotinib, a drug that blocks enzymes thought to be involved in regulating alpha-synuclein levels, in people living with DLB.

This information is current as of July 2022.

Research Implementation Area
AD Related Dementias - Specific
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations

An official website of the National Institutes of Health